Industrial Transformation Training Centres - Grant ID: IC170100022
Funder
Australian Research Council
Funding Amount
$4,420,408.00
Summary
ARC Training Centre for Innovative BioEngineering. The ARC Training Centre for Musculoskeletal Biomedical Technologies will provide the next-generation of skilled graduates to overcome industry-focused challenges in musculoskeletal regeneration. The Centre expects to engineer a set of integrated technologies to personalise implants for the unique biological, physical and lifestyle characteristics of the recipient. Expected outcomes of the Centre include embedded bioelectronic sensors to assess a ....ARC Training Centre for Innovative BioEngineering. The ARC Training Centre for Musculoskeletal Biomedical Technologies will provide the next-generation of skilled graduates to overcome industry-focused challenges in musculoskeletal regeneration. The Centre expects to engineer a set of integrated technologies to personalise implants for the unique biological, physical and lifestyle characteristics of the recipient. Expected outcomes of the Centre include embedded bioelectronic sensors to assess and optimise the healing process. In addition, the Centre will produce data for use in deriving the next-generation of implants, giving rise to improved health outcomes, economic benefits, and a skilled workforce able to advance and perpetuate this important field.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Multivalent drug delivery carrier for the targeted delivery of platinum anticancer agents to hepatocytes. Hepatocellular carcinoma (HCC) is often treated with chemotherapy using cytotoxic drugs. This systemic treatment results in the distribution of the drug throughout the body. Employing a polymer particle as a drug carrier for these drugs ensures a temporal control of the release and therefore supply of the drug within the body. By attaching carbohydrate moieties onto the surface of the polyme ....Multivalent drug delivery carrier for the targeted delivery of platinum anticancer agents to hepatocytes. Hepatocellular carcinoma (HCC) is often treated with chemotherapy using cytotoxic drugs. This systemic treatment results in the distribution of the drug throughout the body. Employing a polymer particle as a drug carrier for these drugs ensures a temporal control of the release and therefore supply of the drug within the body. By attaching carbohydrate moieties onto the surface of the polymer particle the drug carrier can specifically be recognized by cell receptors, thus allowing a targeted delivery of the drug to the desired area in the body. A range of carbohydrate-based drug carriers will be synthesized and tested towards their interaction with hepatocytes to allow optimisation of this drug carrier system.
Read moreRead less
Controlling the adhesome to regulate cell fate on biomaterials. Mesenchymal stem cell-based tissue engineering practices are hampered worldwide by the lack of appreciation and understanding of the matrix-mediated cues that must be provided during adhesion and spreading to drive cells to definitive tissue end points. This project will address these knowledge deficiencies by combining high throughput array technologies, a set of tailorable self-assembling biomaterials and real-time biosensors to r ....Controlling the adhesome to regulate cell fate on biomaterials. Mesenchymal stem cell-based tissue engineering practices are hampered worldwide by the lack of appreciation and understanding of the matrix-mediated cues that must be provided during adhesion and spreading to drive cells to definitive tissue end points. This project will address these knowledge deficiencies by combining high throughput array technologies, a set of tailorable self-assembling biomaterials and real-time biosensors to rapidly, at high resolution, elucidate how mechanotransductive cues determine the fate choice of mesenchymal stem cells, and furthermore, how to manipulate them with smart biomaterial design to achieve desired outcomes for tissue engineering. Read moreRead less
An anti-senescence nanoplatform and its underlying mechanism. The project will bring together complementary expertise and skills by combining biomaterials, cell and molecular biology, and engineering, to develop a novel nano-biomaterial platform for anti-senescence and gain an in-depth understanding of its underlying mechanisms. The underlying mechanisms of senescence remain elusive and bone substitutes with anti-senescence property have not been explored and becoming a growing field of interest ....An anti-senescence nanoplatform and its underlying mechanism. The project will bring together complementary expertise and skills by combining biomaterials, cell and molecular biology, and engineering, to develop a novel nano-biomaterial platform for anti-senescence and gain an in-depth understanding of its underlying mechanisms. The underlying mechanisms of senescence remain elusive and bone substitutes with anti-senescence property have not been explored and becoming a growing field of interest in bone regeneration. The project will develop a well-defined and efficient nanomaterial platform with optimal combination of nano-surface features and chemistry for cell rejuvenation, and it will give unprecedented depth of interdisciplinary understanding of senescence rejuvenation mechanisms.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE150101518
Funder
Australian Research Council
Funding Amount
$345,000.00
Summary
Cellular responses to nanoparticles from cells on micropatterned surfaces. The mechanisms underlying cell-nanoparticle interactions remain largely unknown. It has hampered the design and development of innovative nano devices to be used for drug delivery, biomarkers and diagnostics. This project aims to explore the influences of cell size, density, geometry, intercellular communication and substrate properties on cell-nanoparticle interactions. A micropatterning technology is applied to precisel ....Cellular responses to nanoparticles from cells on micropatterned surfaces. The mechanisms underlying cell-nanoparticle interactions remain largely unknown. It has hampered the design and development of innovative nano devices to be used for drug delivery, biomarkers and diagnostics. This project aims to explore the influences of cell size, density, geometry, intercellular communication and substrate properties on cell-nanoparticle interactions. A micropatterning technology is applied to precisely control cell behaviour and provide a novel in vitro cellular model for nanoparticle studies. This project aims to significantly improve the understanding of cell-nanoparticle interactions to provide new insight into nanoparticle design and improve the efficacy of nano devices.Read moreRead less
Core-shell nanoparticle from polymers with pendant cyclodextrins. A better drug delivery system will be developed for the treatment of cancer with albendazole. These nanoparticles enhance the circulation time in the body, but also facilitate the delivery of the drug to the site of the tumour, which will increase the efficacy of the treatment. The nanoparticles are obtained by processing polymers with pendant cyclodextrin groups, which are a type of complex sugars. Aim of this work is the explora ....Core-shell nanoparticle from polymers with pendant cyclodextrins. A better drug delivery system will be developed for the treatment of cancer with albendazole. These nanoparticles enhance the circulation time in the body, but also facilitate the delivery of the drug to the site of the tumour, which will increase the efficacy of the treatment. The nanoparticles are obtained by processing polymers with pendant cyclodextrin groups, which are a type of complex sugars. Aim of this work is the exploration of synthetic routes to generate nanoparticles. Tailoring the underpinning polymer structure of these nanoparticles will allow the optimisation of the release of albendazole from the drug carrier, thus improving cancer treatment.Read moreRead less
Degradable hollow microspheres for liver cancer treatment. The expected outcome of this multidisciplinary approach is a controlled drug delivery system for the treatment of liver cancer. We aim to increase the understanding of drug release using polymeric microspheres and the influence of the polymer properties on the release kinetics resulting in the tailored drug release for liver cancer treatment. An indepth knowledge in drug delivery can lead to optimised release kinetics leding to an increa ....Degradable hollow microspheres for liver cancer treatment. The expected outcome of this multidisciplinary approach is a controlled drug delivery system for the treatment of liver cancer. We aim to increase the understanding of drug release using polymeric microspheres and the influence of the polymer properties on the release kinetics resulting in the tailored drug release for liver cancer treatment. An indepth knowledge in drug delivery can lead to optimised release kinetics leding to an increased patient convenience and life prolonging treatments.Read moreRead less
Platinum drugs containing core-shell nanoparticles. Many drugs such as cancer drugs contain metal ions. While the therapeutic benefits of metal containing drugs are highly promising, their administration is often accompanied by substantial side effects. Encapsulation of these drugs into nano-sized core-shell particles will prolong the circulation of the drug and therefore reduce the amount of repeated administrations. In addition, the shape and nature of the particle will enable the targeted del ....Platinum drugs containing core-shell nanoparticles. Many drugs such as cancer drugs contain metal ions. While the therapeutic benefits of metal containing drugs are highly promising, their administration is often accompanied by substantial side effects. Encapsulation of these drugs into nano-sized core-shell particles will prolong the circulation of the drug and therefore reduce the amount of repeated administrations. In addition, the shape and nature of the particle will enable the targeted delivery of these drug loaded nanocarriers to the tumor while healthy tissue remains unaffected. Read moreRead less